UTRN and Duchenne muscular dystrophy: Recently, in collaboration with Summit Therapeutics, we developed SMT C1100, an orally bioavailable drug that is able to modulate utrophin levels in the mdx mouse model and human DMD cells in a wide range of muscles, including the heart, diaphragm and skeletal muscles.